Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art

Gastaldi, Lucia; Battaglia, Luigi; Peira, Elena; Chirio, Daniela; Muntoni, Elisabetta; Solazzi, Ilaria; Gallarate, Marina; Dosio, Franco

doi:10.1016/j.ejpb.2014.05.004

Cited by 188 publications

(98 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this dual-drug delivery system, SLNs itself can cross the BBB and deliver the drug molecular to a specific brain site; Myrj52 and HU-211 can be used to modify SLNs and enhance this ability, mainly because Myrj52 can inhibit the function of P-gp and because HU-211 is highly lipophilic. [51][52][53] To confirm the successful fabrication of Cur/SLNs-HU-211, many physicochemical characterizations were performed. Transmission electron microscopy results showed that Cur/SLNs-HU-211 was uniform, which may contribute to better solubility in water and bioavailability in biological system.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

Zhu

Wang

et al. 2016

IJN

View full text Add to dashboard Cite

Major depression is a complex neuropsychiatric disorder with few treatment approaches. The use of nontargeted antidepressants induced many side effects with their low efficacy. A more precise targeting strategy is to develop nanotechnology-based drug delivery systems; hence, we employed solid lipid nanoparticles (SLNs) to encapsulate HU-211 and curcumin (Cur). The antidepressant effects of the dual-drug nanoparticles (Cur/SLNs-HU-211) for major depression treatment were investigated in corticosterone-induced cellular and animal models of major depression. Cur/SLNs-HU-211 can effectively protect PC12 cells from corticosterone-induced apoptosis and can release more dopamine, which may be associated with the higher uptake of Cur/SLNs-HU-211 shown by cellular uptake behavior analysis. Additionally, Cur/SLNs-HU-211 significantly reduced the immobility time in forced swim test, enhanced fall latency in rotarod test, and improved the level of dopamine in mice blood. Cur/SLNs-HU-211 can deliver more Cur to the brain and thus produce a significant increase in neurotransmitters level in brain tissue, especially in the hippocampus and striatum. The results of Western blot and immunofluorescence revealed that Cur/SLNs-HU-211 can significantly enhance the expression of CB1, p-MEK1, and p-ERK1/2. Our study suggests that Cur/SLNs-HU-211 may have great potential for major depression treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

Zhu

Wang

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…Therapeutic nanocarriers can range in size from 1 to 1000 nm and be generated from a wide variety of substances, both biodegradable and non-biodegradable, including polymers, lipids, carbon nanotubes and ceramics (Kreuter 2014, Patel et al 2012, Gastaldi et al 2014). Nanoparticles are especially important for therapeutic delivery to areas that are otherwise difficult to access, such as the central nervous system and areas beyond the blood-brain barrier.…”

Section: Nanoparticlesmentioning

confidence: 99%

Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection

DeMarino

Schwab

Pleet

et al. 2016

J Neuroimmune Pharmacol

View full text Add to dashboard Cite

Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.

show abstract

“…While this therapeutic approach has been successfully applied in vitro , preclinical validation is needed to address potential concerns regarding overexpression of the target protein above endogenous levels as well as safety and efficacy of viral delivery. A novel approach to overcome potential off-target toxicity using viral delivery methods is the use of lipid nanoparticles [171,172], which have been shown recently to efficiently deliver siRNAs into the brain with little apparent toxicity [173]. …”

Section: Potential Therapies Targeting Aberrant Rna Homeostasismentioning

confidence: 99%

Aberrant Rna Homeostasis in Amyotrophic Lateral Sclerosis: Potential for New Therapeutic targets?

Donnelly

Grima

Sattler

2014

Neurodegener. Dis. Manag.

View full text Add to dashboard Cite

Summary Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. The disease pathogenesis is multifaceted in that multiple cellular and molecular pathways have been identified as contributors to the disease progression. Consequently, numerous therapeutic targets have been pursued for clinical development, unfortunately with little success. The recent discovery of mutations in RNA modulating genes such as TARDBP/TDP-43, FUS/TLS or C9ORF72 changed our understanding of neurodegenerative mechanisms in ALS and introduced the role of dysfunctional RNA processing as a significant contributor to disease pathogenesis. This article discusses the latest findings on such RNA toxicity pathways in ALS and potential novel therapeutic approaches.

show abstract

Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art

Cited by 188 publications

References 95 publications

Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection

Aberrant Rna Homeostasis in Amyotrophic Lateral Sclerosis: Potential for New Therapeutic targets?

Contact Info

Product

Resources

About